摘要
目的 :研究大豆异黄酮对高胆固醇血症大鼠血液及肝脏丙二醛 (MDA )、超氧化物歧化酶(SOD)的影响。方法 :根据血胆固醇水平 ,5 0只雄性Wistar大鼠随机分为 5组 ,正常对照组 (NC)、高胆固醇血症对照组 (HC)和 3个大豆异黄酮治疗组。除正常对照组以外 ,各组均喂以高胆固醇饲料。同时 ,3个治疗组分别灌胃给予 30 ,6 0 ,12 0mg·kg- 1大豆异黄酮 ,对照组给予相应的溶媒 ,持续 9wk。实验结束时 ,分离血清、红细胞 ,取出肝脏 ,制备肝匀浆。采用黄嘌呤氧化酶法测定红细胞和肝匀浆SOD活力 ,以硫代巴比妥酸法测定血清和肝匀浆MDA含量。结果 :与正常对照组比较 ,高胆固醇血症对照组大鼠红细胞及肝匀浆SOD活力明显降低。大豆异黄酮 6 0和 12 0mg·kg- 1组大鼠红细胞及肝脏SOD活力比高胆固醇血症对照组明显升高 (P <0 .0 1和P <0 .0 5 )。高胆固醇血症对照组大鼠血清及肝匀浆MDA含量与正常对照组比较明显升高。与高胆固醇血症对照组比较 ,大豆异黄酮 30和 6 0mg·kg- 1组大鼠血清MDA含量及 30和 12 0mg·kg- 1组大鼠肝脏MDA含量明显降低 (P <0 .0 5 )。结论 :对于高胆固醇血症大鼠红细胞及肝脏SOD活力的降低及血清和肝脏MDA水平的升高 。
AIM: To investigate the effect of soy isoflavones (SI) on malondialdehyde (MDA) and superoxide dismutase (SOD) of blood and liver in hypercholesterolemia rats. METHODS: According to serum cholesterol level, fifty male Wistar rats were randomly divided into five groups: normal control group (NC), hypercholesterolemia control group (HC) and three SI treatment groups. Rats were fed with high cholesterol food except NC group rats. At the same time, SI 30, 60, 120 mg·kg -1 were given intragastrically (ig) in three SI treatment groups, and solvent in two control groups for 9 wk. At the end of the treatment, either serum or red blood cell (RBC) was isolated, liver was dissected out and liver homogenate was prepared. SOD activities in RBC and liver were measured by xanthine oxidase method. Serum and hepatic MDA contents were assayed according to thiobarbituric acid method. RESULTS: SOD activities in RBC and liver were significantly lower in HC group than those in NC group. Compared with HC group, SOD activities in RBC and liver were significantly increased in SI 60 mg·kg -1 and 120 mg·kg -1 groups (P< 0.01 and P<0.05). Serum and hepatic MDA contents were significantly higher in HC group than those in NC group. Compared with HC group, serum and hepatic MDA contents in SI treated groups were significantly decreased (P<0.05). CONCLUSION: SI can increase SOD activities in RBC and liver and decrease serum and hepatic MDA contents in hypercholesterolemia rats.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第5期257-261,共5页
Chinese Journal of New Drugs and Clinical Remedies